Serelaxin Treatment Reduces Oxidative Stress and Increases Aldehyde Dehydrogenase-2 to Attenuate Nitrate Tolerance by Chen Huei Leo et al.
fphar-08-00141 March 18, 2017 Time: 15:45 # 1
ORIGINAL RESEARCH
published: 21 March 2017
doi: 10.3389/fphar.2017.00141
Edited by:
Paul H. Ratz,
Virginia Commonwealth University,
USA
Reviewed by:
Silvia Nistri,
University of Florence, Italy
Kirk Peter Conrad,
University of Florida, USA
Philip Aaronson,
King’s College London, UK
*Correspondence:
Chen Huei Leo
chenhuei_leo@sutd.edu.sg
†Present address:
Chen Huei Leo
Science and Maths Cluster,
Singapore University of Technology
and Design, Singapore, Singapore
‡These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 30 November 2016
Accepted: 07 March 2017
Published: 21 March 2017
Citation:
Leo CH, Fernando DT, Tran L,
Ng HH, Marshall SA and Parry LJ
(2017) Serelaxin Treatment Reduces
Oxidative Stress and Increases
Aldehyde Dehydrogenase-2
to Attenuate Nitrate Tolerance.
Front. Pharmacol. 8:141.
doi: 10.3389/fphar.2017.00141
Serelaxin Treatment Reduces
Oxidative Stress and Increases
Aldehyde Dehydrogenase-2 to
Attenuate Nitrate Tolerance
Chen Huei Leo*†‡, Dhanushke T. Fernando†, Lillie Tran, Hooi Hooi Ng, Sarah A. Marshall
and Laura J. Parry
School of BioSciences, The University of Melbourne, Parkville, VIC, Australia
Background: Glyceryl trinitrate (GTN) is a commonly prescribed treatment for
acute heart failure patients. However, prolonged GTN treatment induces tolerance,
largely due to increased oxidative stress and reduced aldehyde dehydrogenase-2
(ALDH-2) expression. Serelaxin has several vasoprotective properties, which include
reducing oxidative stress and augmenting endothelial function. We therefore tested the
hypothesis in rodents that serelaxin treatment could attenuate low-dose GTN-induced
tolerance.
Methods and Results: Co-incubation of mouse aortic rings ex vivo with GTN
(10 µM) and serelaxin (10 nM) for 1 h, restored GTN responses, suggesting that
serelaxin prevented the development of GTN tolerance. Male Wistar rats were
subcutaneously infused with ethanol (control), low-dose GTN+placebo or low-dose
GTN+serelaxin via osmotic minipumps for 3 days. Aortic vascular function and
superoxide levels were assessed using wire myography and lucigenin-enhanced
chemiluminescence assay respectively. Changes in aortic ALDH-2 expression were
measured by qPCR and Western blot respectively. GTN+placebo infusion significantly
increased superoxide levels, decreased ALDH-2 and attenuated GTN-mediated
vascular relaxation. Serelaxin co-treatment with GTN significantly enhanced GTN-
mediated vascular relaxation, reduced superoxide levels and increased ALDH-2
expression compared to GTN+placebo-treated rats.
Conclusion: Our data demonstrate that a combination of serelaxin treatment with
low dose GTN attenuates the development of GTN-induced tolerance by reducing
superoxide production and increasing ALDH-2 expression in the rat aorta. We suggest
that serelaxin may improve nitrate efficacy in a clinical setting.
Keywords: serelaxin, aldehyde dehydrogenase-2, aorta, nitrates, oxidative stress
Abbreviations: ACh, acetylcholine; ALDH-2, aldehyde dehydrogenase-2; cGMP, cyclic guanosine monophosphate; COX,
cyclooxygenase; DHFR, dihydrofolate reductase; EDH, endothelium-derived hyperpolarization; eNOS, endothelial nitric
oxide synthase; GTN, glyceryl trinitrate; GTPCH, GTP cyclohydrolase-1; IKCa, intermediate-conductance calcium-activated
K+ channel; iNOS, inducible nitric oxide synthase; L-NAME, Nω-nitro-L-arginine methyl ester hydrochloride; NO, nitric
oxide; PGI2, prostacyclin; ROS, reactive oxygen species; RXFP1, relaxin/insulin-like family peptide receptor 1.
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INTRODUCTION
Organic nitrates such as nitroglycerin (GTN) are widely used for
the acute treatment of heart diseases including chronic congestive
heart failure, coronary artery disease and acute heart failure
(AHF) (Daiber and Münzel, 2015). The beneficial effects of
nitrates are mainly associated with their ability to dilate venous
capacitance vessels, coronary arteries and the aorta, thereby
improving left ventricular function and reducing myocardial
workload (Abrams, 1995). The mechanisms underlying this
vasodilation involve release of NO (and the metabolite 1,2
glyceryl dinitrite) in response to intracellular biotransformation
of GTN by the ALDH-2 enzyme (Chen et al., 2002). This
results in activation of soluble guanylate cyclase (sGC), leading to
increased cyclic guanosine-3′,-5′-monophosphate (cGMP) levels
and relaxation of the vascular smooth muscle (Münzel et al.,
2005). GTN-dependent vasodilation of isolated aortic rings is
reduced by daidzin, a highly specific inhibitor of ALDH-2 (Sydow
et al., 2004). Moreover, mice deficient in mitochondrial ALDH-
2 show impaired relaxation specifically to GTN, but not other
nitrovasodilators such as sodium nitroprusside in the aorta (Chen
et al., 2002).
Long-term continuous administration of organic nitrates has
its limitations because of the rapid development of tolerance,
cross tolerance to other nitrovasodilators, and endothelial
dysfunction (Münzel et al., 2005, 2011). Patients treated with
clinically relevant, low-dose GTN for 48 h develop tolerance
to GTN and endothelial dysfunction in arterial and venous
vessels. This is associated with decreased vascular expression of
ALDH-2 and activity, and increased ROS production (Schulz
et al., 2002; Hink et al., 2007). Interestingly, higher doses of
GTN are routinely used to induce GTN tolerance and endothelial
dysfunction in rodent vessels (Mülsch et al., 2001; Sydow et al.,
2004; Wenzel et al., 2008). The effects of clinically relevant, low-
dose GTN treatment on rodent vessels are less well-studied,
particularly the development of tolerance and/or endothelial
dysfunction. The mechanisms that lead to nitrate tolerance
involve multiple factors, including impaired biotransformation
of organic nitrates to NO, desensitization of sGC receptors,
increased activity of phosphodiesterase, and increased vascular
superoxide production (Münzel et al., 2005, 2011). This latter
feature is a major limitation for the clinical use of GTN because
oxidative stress induction is a characteristic of cardiovascular
disease and actively contributes to its progression.
The recombinant form of human relaxin-2 (serelaxin)
has emerged as a potential drug with long-term therapeutic
advantages for patients with AHF (Teerlink et al., 2013).
Follow-up studies in AHF patients reported that intravenous
infusion of serelaxin rapidly reduced systemic vascular resistance
(Ponikowski et al., 2014), an effect likely to be mediated
through a vasodilatory action of serelaxin on systemic arteries
as demonstrated in many animal studies and humans (Jeyabalan
et al., 2003; Conrad, 2010; McGuane et al., 2011b; Leo
et al., 2016a). The vascular actions of serelaxin occur through
activation of the RXFP1, localized within the endothelium
and smooth muscle cells of several arteries and veins,
including the aorta (Jelinic et al., 2014; Ng et al., 2015).
Serelaxin treatment in rats enhances endothelium-dependent
relaxation via a combination of NO, EDH, and prostacyclin
(PGI2). The contribution of these vasodilator pathways is
influenced by duration of serelaxin treatment and varies between
vascular beds (Jelinic et al., 2014; Leo et al., 2014b, 2016a,b).
Under conditions of vascular dysfunction, serelaxin also has
vasoprotective functions. Incubation of rat aortic rings with
tumor necrosis factor-α ex vivo increased ROS production
and impaired ACh-induced relaxation. Co-incubation of these
aortic rings with serelaxin caused PI3K-dependent eNOS
dephosphorylation at Thr495, eNOS phosphorylation at Ser1177
and Ser633, attenuated arginase II expression (Dschietzig et al.,
2012), increased eNOS activity and improved ACh-mediated
endothelium-dependent relaxation. Serelaxin treatment also
reduced superoxide and nitrotyrosine levels (Dschietzig et al.,
2012). Similarly, serelaxin treatment prevented aorta endothelial
dysfunction under conditions of acute hyperglycemia (Ng et al.,
2016) and chronic exposure to cigarette smoke (Pini et al., 2016).
Prevention of endothelial dysfunction was partly explained by the
reduction of oxidative stress and an upregulation of eNOS and
PGI2 activity (Ng et al., 2016; Pini et al., 2016). Therefore, a key
mechanism of serelaxin action is to maintain vascular function by
reducing oxidative stress.
Interestingly, ancillary observations made during a clinical
study in which patients with peripheral arterial disease were
treated with relaxin intramuscularly for at least 3 months were
suggestive of improvements in their nitroglycerin requirements.
3/20 patients with prior myocardial infarction and active angina
were treated with nitroglycerin. Interestingly, all of these patients
reported that their reliance on nitroglycerin was declined when
relaxin was co-administered (Casten et al., 1960; Raleigh et al.,
2016). Thus, serelaxin could perform two important functions
in the vasculature of AHF patients who may require acute GTN
therapy: (i) synergistic action with GTN to reduce systemic
vascular resistance through a vasodilatory action, and (ii) prevent
the development of tolerance to GTN (or other organic nitrates).
Therefore, the aims of the present study were to investigate
whether or not serelaxin attenuates GTN tolerance in the aorta
using ex vivo studies in mice and in vivo experiments in
rats. Our underlying hypothesis was that serelaxin attenuates
GTN-induced overproduction of vascular ROS by increasing
ALDH-2.
MATERIALS AND METHODS
All procedures were approved by the Faculty of Science
Animal Experimentation Ethics Committee (The University of
Melbourne, AEC1312780.1 and AEC1312840.1) and conformed
to the National Health and Medical Research Council of Australia
code of practice for the care and use of animals for scientific
purposes.
Animals
Male C57BL/6J mice (body weight 25–30 g) and Wistar rats
(body weight 200–250 g) were purchased from the Animal
Resource Centre (Canning Vale, WA, Australia). The animals
Frontiers in Pharmacology | www.frontiersin.org 2 March 2017 | Volume 8 | Article 141
fphar-08-00141 March 18, 2017 Time: 15:45 # 3
Leo et al. Prevention of Nitrate Tolerance by Serelaxin
were housed in the School of BioSciences Animal House Facilities
(The University of Melbourne) in a 12L:12D cycle at 20◦C, with
standard food pellets (Barastock, Pakenham, VIC, Australia) and
water provided ad libitum.
Vascular Reactivity
Mice were killed via cervical dislocation under 2% isofluorane
anesthesia and the aortae were isolated, cleared of fat and
connective tissue, and cut into 1–2 mm long rings and mounted
on a Mulvany–Halpern myograph (model 610 M, Danish Myo
Technology, Aarhus, Denmark) using two 40 µm stainless steel
wire. The output from the myograph was recorded and analyzed
using a PowerLab data acquisition system and the program
LabChart (ADInstruments, Bella Vista, NSW, Australia). The
remainder of the aorta was snap frozen in liquid nitrogen and
stored at −80◦C for further analysis. After the aortic rings were
mounted on the myograph, they were allowed to stabilize at
zero tension for 15 min. After stabilization, the vessels were
stretched to 5 mN during a normalization period of 45 min,
and then maximally contracted using either high potassium
saline solution (KPSS) or the thromboxane A2 mimetic, U46619
(1 µM). To confirm endothelium integrity, vessels were pre-
contracted to 50% of the maximum KPSS response using
phenylephrine (PE) (10–50 nM) or U46619 (10–50 nM), and
then relaxed with the endothelium-dependent agonist ACh. The
endothelium was considered to be functional if relaxation to
ACh was >80% as described previously for the mouse (Ng
et al., 2015) and rat aortae (Leo et al., 2016c). All experiments
were performed at 37◦C in the presence of 95% O2 and 5%
CO2.
Ex vivo Tolerance Experiments
The aortic rings were then incubated in either placebo (20 mM
sodium acetate) or in the presence of GTN (1, 10, 30, or 100µM),
or serelaxin (1, 3, or 10 nM; kindly provided by Novartis Pharma
AG, Switzerland) for a period of 60 min. Aortic rings were
washed thoroughly every 15 min for 1 h after incubation. These
concentrations of serelaxin were previously shown to result in
vasodilation (McGuane et al., 2011a; Dschietzig et al., 2012;
Ng et al., 2016). The vessels were pre-contracted to ∼50%
of maximal contraction with the thromboxane A2 mimetic,
U46619 (10–50 nM), and concentration-response curves to
GTN (0.1 nM–10 µM) were obtained. At the end of the
response curves, 10 µM of the endothelium-independent dilator
levcromakalim (LVK) was added to induce maximum relaxation.
To investigate if serelaxin treatment prevents tolerance to GTN
ex vivo, the aortae were incubated with placebo alone or 10 µM
of GTN in combination with serelaxin (3 or 10 nM) for 1-h,
followed by a 1-h washout period. Subsequently, concentration-
response curves to GTN (0.1 nM–10 µM) were evaluated in
∼50% pre-contracted aortae. Only one concentration response
curve was performed on each aortic ring.
In vivo Tolerance Model
Male Wistar rats were randomly divided into three groups: (i)
controls (n = 14), (ii) GTN + placebo (n = 16), and (iii) GTN
+ serelaxin (n = 15). The rats were implanted with osmotic
minipumps (Alzet Model 2001, Bioscientific, Gymea, NSW,
Australia) to infuse low dose GTN (5µg h−1) (Schulz et al., 2002;
Hink et al., 2007) and/or serelaxin (4 µg h−1) (Leo et al., 2016c)
subcutaneously under the back of the skin for 3 days. There was
no control+serelaxin group because we have previously reported
that serelaxin treatment for 3 days had no significant effects in
the aorta under control conditions (Leo et al., 2016c). The control
rats received placebo solution which was either ethanol or 20 mM
sodium acetate. The dose of GTN and serelaxin were chosen to
mimic clinically relevant concentrations in the treatment of acute
coronary syndrome and acute myocardial infarction (Jugdutt and
Warnica, 1989) and RELAX-AHF clinical trial (Teerlink et al.,
2013) respectively.
Following 3 days of infusion, blood samples were obtained
from the left ventricle via cardiac puncture under 2% isofluorane
anesthesia. The rats were then killed by bilateral chest incision
through the diaphragm and removal of the heart. Plasma
concentrations of serelaxin (n = 8–10 per group) were measured
in duplicate using the Human Relaxin-2 Quantikine ELISA
Kit (R&D Systems, Minneapolis, MN, USA) following the
manufacturer’s protocol. The limit of detection was 15.6 pg/ml
and the intra- and inter coefficients of variation were 2.3–4.7
and 5.5–10.2%, respectively. The abdominal aorta was isolated
and prepared for vascular reactivity experiments using the
wire-myograph as described earlier. The aortic rings were pre-
contracted to∼50% of maximal contraction with phenylephrine,
PE (1–10 µM) and concentration-response curves to GTN
(0.1 nM–10 µM), the NO donor, diethylamine NONOate
(DEA/NO, 0.1 nM–10 µM) and the endothelium-dependent
vasodilator, ACh (1 nM–10 µM) were obtained. Only one
concentration response curve to each vasodilator was performed
on each aortic ring. To examine the basal NO activity,
endothelium-intact aortic rings were sub-maximally contracted
with PE (10–100 nM) to ∼20% of maximal contraction followed
by the addition of the NOS inhibitor, L-NAME (200 µM). Under
these conditions, a contractile response to L-NAME is considered
to reflect the level of basal NOS activity (Leo et al., 2011; Kahlberg
et al., 2016).
Assessment of Reactive Oxygen Species
Superoxide anion production in the rat aortae was determined
by lucigenin-enhanced chemiluminescence assay as previously
described (Leo et al., 2012). Briefly, three 2 mm rings were
cut and placed in wells containing modified Krebs- HEPES
buffer (containing in mM 99.9 NaCl, 4.7 KCl, 1.2 MgSO4,
1 KH2PO4, 25 NaHCO3, 20 Na-HEPES, 11 glucose, and 2.5
CaCl2). To assess NADPH oxidase driven superoxide production,
two rings were stimulated with NADPH (100 µM). One
ring was exposed to the flavoprotein inhibitor that inhibits
NADPH oxidase, diphenyliodonium (DPI, 5 µM). Tissue
segments were first incubated with the superoxide dismutase
(SOD) inhibitor DECTA (3 mM) for 45 min at 37◦C and
then washed for 2 min. They were then transferred to wells
containing lucigenin (5 µM) and measured for luminescence
in a FLUOstar Omega filter-based multimode microplate reader
(BMG LABTECH, Melbourne, VIC, Australia). Superoxide
production was calculated by subtracting the chemiluminescence
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signal obtained in blank wells from the signal detected in the
well-containing the aortic ring and then normalized to dry tissue
weight (mg).
Western Blotting
Frozen endothelium-intact rat aortae were placed in a pre-
chilled Wig-L-Bug R© capsule with a metal ball and pulverized
with a Digital Wig-L-Bug R© amalgamator (Dentsply, Ltd, York,
PA, USA). Protein extraction and western blot were performed
as described previously (Leo et al., 2010). Briefly, samples were
dissolved in 300 µL of ice-cold lysis buffer (100 mmol L−1
NaCl, 10 mmol L−1 Tris, 2 mmol L−1 EDTA, 0.5% w/v sodium
deoxycholate, 1% vol/vol triton X-100, pH 7.4) with a protease
and phosphatase inhibitor cocktail according to manufacturer’s
instructions (Roche, Sydney, NSW, Australia). Total protein
concentration of the samples was quantified using a BCA protein
assay kit (ThermoScientific, Rockford, IL, USA). Equal amounts
(20 µg) of protein homogenate were subjected to SDS-PAGE
(10%) and Western blot analysis using rabbit primary antibodies
(1:250, overnight, 4◦C) against ALDH-2 (ABCAM, Cambridge,
CB, UK). To normalize for the amount of protein, membranes
were re-probed with actin (Sigma-Aldrich, St. Louis, MO,
USA), which served as a loading control (1:2000). All proteins
were detected by enhanced chemiluminescence (Amersham,
GE Healthcare Life Sciences, Sydney, NSW, Australia) after
incubation with HRP-conjugated secondary antibody (Millipore,
Billerica, MA, USA) for 1 h at room temperature (1:2000).
All protein bands were quantified by densitometry (Biorad
Chemidoc, Sydney, NSW, Australia) and expressed as a ratio of
the loading control.
RNA Extraction and Quantitative PCR
Frozen rat aortae were pulverized as described previously
(Leo et al., 2014a). Pulverized tissues were resuspended in
1 ml TriReagent (Ambion, Inc., Scoresby, VIC, Australia) and
total RNA was then extracted according to the manufacturer’s
instructions. RNA pellets were resuspended in 20 µl RNA
SecureTM (Ambion). Quality and quantity of RNA were
determined using the NanoDrop ND1000 Spectrophotometer
(Thermo Fisher Scientific Australia Pty Ltd, Scoresby, VIC,
Australia) with A260:A280 ratios> 1.8 indicating sufficient quality
for qPCR analysis. First strand cDNA synthesis used 1 µg of
total RNA in a 20 µl reaction containing random hexamers
(50 ng µL−1) and 200 units of SuperscriptTM III (Invitrogen,
Mulgrave, VIC, Australia). First-strand cDNA synthesis for all
samples were performed simultaneously at 25◦C for 10 min,
50◦C for 50 min, and 85◦C for 5 min. The comparative
cycle threshold (2−1Ct) method of qPCR was used to analyze
Aldh2, eNOS (Nos3), Dhfr, and Gch1 gene expression in the
rat aortae. The latter two genes code for two enzymes that
are involved in the regulation of the intracellular levels of
the eNOS cofactor tetrahydrobiopterin (BH4), which preserves
eNOS dimerization and improves endothelial function. Rat-
specific forward/reverse primers and 6-carboxyl fluorescein-
labeled (FAM) Taqman probes were designed and purchased
from Biosearch Technologies (Table 1, Novato, CA, USA).
Primers were designed to span intron/exon boundaries. qPCR
was performed on the Applied Biosystems ViiA7 PCR machine
(Life Technologies, Mulgrave, VIC, Australia) using 96-well
plates with 10 µl volume reactions in triplicate containing
SensiFASTTM Probe Lo-Rox (BioRad, West Ryde, NSW,
Australia) and 10 µmol L−1 of primers and FAM-labeled probe.
Ribosomal 18S (Rn18s) was used as the reference gene. Negative
template controls substituting cDNA with water or RT negative
controls substituting the reverse transcriptase in the cDNA
synthesis were included on each plate. For each sample, the mean
Rn18s CT triplicate value was subtracted from the mean gene of
interest triplicate CT value, and normalized to the reference gene.
These normalized data (1Ct) were then presented as a relative
value (mean± SEM).
TABLE 1 | Forward and reverse primers of genes of interest.
Gene Sequence Accession ID
r18S FAM
r18S Fwd
r18S Rev
TGGAGCGATTTGTCTGGTTAATTCCGA
GCATGGCCGTTCTTAGTTGG
TGCCAGAGTCTCGTTCGTTA
NR_046237.1
rALDH2 FAM
rALDH2 Fwd
rALDH2 Rev
TGTGGTCAATATTGTTCCTGGA
CACCGCTCACTGCACTCTAC
AAGGCCACTTTGTCCACATC
NM_032416.1
rDHFR FAM
rDHFR Fwd
rDHFR Rev
GTAAAGTGGACATGGTCTGGGT
TGCCAAAAGTCTGGATGATG
CTGATTCATGGCTTCCTGGT
NM_130400.2
rGCH1 FAM
rGCH1 Fwd
rGCH1 Rev
ATGGTGATTGTGAAGGACATTG
CACCAAGGGATACCAGGAGA
AGGTGATGCTCACACATGGA
NM_024356.1
rNOS3 FAM
rNOS3 Fwd
rNOS3 Rev
CCGATACAACATACTTGAGG
ATGAGTTCAGAGATTGGCATGA
TTTCCACAGTGATGAGGTTGTC
NM_021838.2
TaqMan probes were labeled with FAM. Sequences were acquired from the NCBI nucleotide database.
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Reagents
All drugs were purchased from Sigma-Aldrich (St. Louis, MO,
USA), except for U46619 and DEA/NO (Cayman Chemical, Ann
Arbor, MI, USA), LVK (Tocris Chemicals, Bristol, UK) and GTN
(Hospira, Melbourne, VIC, Australia). They were all dissolved
in distilled water, with the exception of GTN and U46619,
which were dissolved in 100% ethanol (final concentration less
than 0.1% ethanol) as 1 mmol/l stock solution and subsequent
dilutions were in distilled water. DEA/NO was dissolved in 0.1 M
NaOH. Diphenyliodonium and LVK were dissolved in 100%
DMSO (final concentration less than 0.1% DMSO).
Statistical Analyses
All results are expressed as the mean ± standard error of
the mean (SEM), n represents the number of animals per
group. Concentration-response curves were computer fitted to
a sigmoidal curve using non-linear regression (Prism version
5.0, GraphPad Software, USA) to calculate the sensitivity against
each agonist (pEC50). Maximum relaxation (Rmax) to ACh, GTN,
or DEA/NO was measured as a percentage of pre-contraction
recorded at highest concentration. Statistical differences between
group pEC50 and Rmax values, superoxide levels and protein/gene
expression were all compared via one-way ANOVA with post hoc
Dunnett’s or Tukey’s tests where appropriate (Prism version 5.0,
GraphPad Software, USA). P < 0.05 was considered statistically
significant.
RESULTS
Serelaxin Attenuates Development of
Tolerance to GTN in the Mouse Aorta
Ex vivo
Incubation of mouse aortic rings with 10, 30, and 100 µM,
but not 1 µM, of GTN for 1 h followed by a 1 h washout
period caused a significant (P < 0.01) decrease in the sensitivity
and maximum relaxation to GTN in a concentration-dependent
manner (Figure 1A), indicating the development of tolerance
to GTN ex vivo. Analysis of the area under the curve for
GTN-mediated relaxation also produced similar findings (data
not shown). To explore if serelaxin could attenuate GTN
tolerance ex vivo, mouse aortic rings were co-incubated with
GTN (10 µM) and serelaxin (10 nM) for 1 h with a 1 h
washout period. This significantly increased (P < 0.05) both
the sensitivity and maximum relaxation to GTN compared
with aortae that were co-incubated with GTN and placebo
(Figure 1B). However, a lower concentration of serelaxin (3 nM)
with 10µM of GTN did not significantly improved the sensitivity
FIGURE 1 | (A) Concentration-response curves, sensitivity (pEC50) and maximum relaxation (Rmax) to GTN after 1 h incubation of (A) either control or GTN (1, 10,
30, 100 µM), (B) control, 10 µM GTN+placebo, 10 µM GTN+3 nM serelaxin, 10 µM GTN+10 nM serelaxin, (C) either placebo or serelaxin (1, 3, 10 nM), followed
by 1 h washout. Data are expressed as mean ± SEM, n = 5–8 per group. ∗P < 0.05 compared to control (one-way ANOVA, Dunnett’s test) #P < 0.05 vs. 10 uM
GTN+placebo (one-way ANOVA, Dunnett’s test).
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and maximum relaxation to GTN. Incubation of mouse aortic
rings with serelaxin (1, 3, and 10 nM) had no effect on the
sensitivity and maximum response to subsequent incubation in
GTN (Figure 1C).
Serelaxin Attenuates GTN Tolerance and
Reduces Superoxide Production in the
Rat Aorta In vivo
Mean plasma concentrations of serelaxin in the GTN+serelaxin
co-treated rats after 3 days of infusion was 79.2 ± 10.3 ng/mL
(range: 51.0–116.3 ng/mL, mean concentration equivalent to
∼13.2 nM, n = 8). Serelaxin was not detectable in the plasma
of control and GTN+placebo rats. Continuous infusion of low-
dose GTN for 3 days resulted in the development of tolerance
to GTN, demonstrated by a significant reduction in both the
sensitivity (F2,27 = 5.34, P = 0.01) and maximum relaxation
(F2,27 = 5.66, P = 0.02) to GTN (Figures 2A,B and Table 2)
in the rat aorta compared with control rats. Conversely, co-
treatment of rats with GTN+serelaxin significantly increased the
sensitivity (P = 0.04) and maximum relaxation (P = 0.02) to
GTN compared with GTN+placebo, indicating that serelaxin
co-treatment prevented GTN tolerance in vivo. Superoxide
production in the aorta was significantly (F2,28 = 7.72, P= 0.002)
increased in the GTN+placebo rats compared with control
rats, whereas co-treatment of GTN-infused rats with serelaxin
significantly (P= 0.04) attenuated superoxide levels (Figure 2C).
Serelaxin Attenuates the Reduction of
ALDH-2 Expression in the Aorta of
GTN-Treated Rats
Continuous infusion of low-dose GTN for 3 days significantly
(F2,27 = 5.03, P = 0.02) reduced both gene (Figure 3A) and
protein (Figure 3B) expression of ALDH-2 in the rat aorta. These
negative effects of GTN on Aldh-2 gene expression (P = 0.03)
were prevented in the aorta of rats co-treated with serelaxin for
3 days (Figure 3A). A similar effect was observed on ALDH-2
protein expression (Figure 3B) but it failed to reach statistical
significance (P = 0.09).
To address if serelaxin alone had any effect on ALDH-2
expression in the rat aorta, we utilized aortic protein extract of
control and control+serelaxin from our recently published work
(Leo et al., 2016c), and analyzed ALDH-2 expression. Although
direct comparison cannot be made with samples collected from
the present GTN study, the data from Figure 4 suggested that
serelaxin treatment alone had no significant effect on ALDH-2
expression in the rat aorta.
Serelaxin Does Not Improve Endothelial
Function and Cross-Tolerance
Low-dose GTN infusion for 3 days resulted in comparable
responses to the nitrovasodilator, DEA/NO (Figure 5A and
Table 2) or ACh (Figure 5B and Table 2) in the aorta compared
with control, indicating that low-dose GTN treatment had no
effect on the development of cross-tolerance or endothelial
dysfunction. Similarly, serelaxin co-treatment also had no
significant effect on the responses to DEA/NO (Figure 5A
and Table 2) or ACh (Figure 5B and Table 2) in the aorta.
This is consistent with our recently published data (Leo et al.,
2016c), showing that serelaxin treatment alone for 3 days did not
affect ACh responses (pEC50; placebo: 6.24 ± 0.07 vs. serelaxin:
6.38± 0.11) in the aorta.
In addition to the lack of endothelial dysfunction, low-
dose GTN treatment had no significant effect on mRNA
expression of Nos3 and enzymes that are involved in eNOS
uncoupling, GTPCH-1 and DHFR. Furthermore, expression of
Gch1 in the aorta (Figure 6A) did not differ significantly in
the GTN+serelaxin compared with control or GTN+placebo
groups. Similarly, there were no significant effects of serelaxin
treatment on Nos3 (Figure 6C) orL-NAME-induced contraction
(Figure 6D), indicating that basal NOS activity was not affected
by GTN+placebo or GTN+serelaxin infusion. Of note, although
GTN+placebo infusion for 3 days had no effect on Dhfr
expression compared to control (Figure 6B), GTN+serelaxin
co-treatment significantly (P = 0.04) increased Dhfr expression
compared to GTN+placebo.
DISCUSSION
The aims of the present study were to investigate whether
or not serelaxin attenuates low-dose GTN tolerance using
FIGURE 2 | Concentration-response curve to (A) GTN and (B) sensitivity to GTN in endothelium-intact aorta from control, GTN+placebo or GTN+serelaxin rats
for 3 days. (C) Aortic superoxide production measured by lucigenin-enhanced chemiluminescence assay from control, GTN+placebo or GTN+serelaxin rats for
3 days. Values are expressed as mean ± SEM, n = 8–11 per group. ∗P < 0.05, significantly different to control, #P < 0.05, significantly different to GTN+placebo
(one-way ANOVA, Tukey’s test). Maximum relaxation (Rmax) values are shown in Table 2.
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TABLE 2 | A comparison of sensitivity (pEC50) and maximum relaxation (Rmax) to GTN, DEA/NO and ACh in endothelium-intact aorta isolated from
control, GTN+placebo and GTN+serelaxin treated rats.
Control GTN+placebo GTN+serelaxin
Vasodilators pEC50 Rmax (%) pEC50 Rmax (%) pEC50 Rmax (%)
GTN 7.04 ± 0.04 94 ± 2 6.55 ± 0.05∗ 86 ± 3∗ 6.96 ± 0.04# 94 ± 1#
DEA/NO 6.81 ± 0.05 100 ± 1 6.84 ± 0.05 101 ± 1 6.92 ± 0.06 101 ± 1
ACh 6.18 ± 0.04 90 ± 4 6.28 ± 0.04 88 ± 2 6.18 ± 0.03 95 ± 4
n = 6–11. Results are shown as mean ± SEM. ∗P < 0.05 versus control, #P < 0.05 versus GTN+placebo, one-way ANOVA with Tukey’s post hoc analysis.
FIGURE 3 | (A) Quantitative analysis of Aldh2 mRNA expression and (B) Western blot analysis of ALDH-2 protein expression in the aorta from control, GTN+placebo
or GTN+serelaxin rats for 3 days. Values are 2-1Ct ± SEM, n = 8–11 per group. Representative blot of ALDH-2 protein expression is shown above the respective
panels, n = 5–6 per group. ∗ Significantly different to control, # significantly different to GTN+placebo, P < 0.05 (one-way ANOVA, Tukey’s post hoc test).
ex vivo and in vivo rodent models of GTN tolerance. In
the ex vivo model, we demonstrated GTN tolerance in the
mouse aorta after 1 h of exposure. Co-incubation of GTN and
serelaxin reversed GTN tolerance. In the in vivo rat model,
continuous infusion of low-dose GTN for 3 days reduced
the vasodilator response to GTN in the aorta, indicating
development of GTN tolerance. This was underpinned by
reduced vascular ALDH-2 expression and increased superoxide
production. Consistent with the ex vivo finding, serelaxin
co-infused with low-dose GTN for 3 days enhanced the
vasodilator action of GTN and attenuated the development of
GTN tolerance. This was accompanied by increased ALDH-
2 expression and reduced superoxide production in the
aorta.
Glyceryl trinitrate is the most commonly used vasodilator
agent for patients with AHF. Unfortunately, the therapeutic
efficacy and vasodilator properties of GTN are rapidly blunted
with prolonged treatment due to the development of nitrate
tolerance (Gori et al., 2001; Münzel et al., 2005, 2011; Schulz
et al., 2011). Serelaxin has emerged as a novel vasoprotective
peptide (Leo et al., 2016b) with beneficial effects in AHF patients,
who were also administered with low dose nitrates (less than
100 µg/kg/h) as standard care (Teichman et al., 2010; Teerlink
et al., 2013). In our ex vivo study, we provided evidence
that serelaxin reverses nitrate tolerance induced by prolonged
exposure to GTN in the aorta. Previous studies demonstrated that
serelaxin directly activates the sGC-cGMP dependent pathway
in adult and fetal vascular smooth muscle cells (Bani et al.,
1998; Failli et al., 2005; Sarwar et al., 2015, 2016) and more
recently in the kidneys (Wetzl et al., 2016). This suggests
that serelaxin could reverse GTN tolerance by increasing the
activity of sGC, which will enhance the vasodilator action of
nitrates. In the current study, we showed that incubation of
increasing concentrations of serelaxin ex vivo had no effect on
the GTN vasodilator response in the mouse aorta, implying
that serelaxin does not interfere with the vasodilator capacity of
GTN. Therefore, it is unlikely that serelaxin enhances the sGC
activity to augment GTN vasodilator responses. Nonetheless,
the ex vivo experiment provided “proof of concept” evidence
that serelaxin has the ability to attenuate GTN tolerance.
Another possible mechanism of serelaxin action is through GTN
biotransformation.
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FIGURE 4 | Western blot analysis of ALDH-2 protein expression in the
aorta from control, control+serelaxin rats for 3 days. Protein extracts
used in this experiment were previously published in Leo et al. (2016c).
Representative blot of ALDH-2 protein expression is shown above the
respective panels, n = 6–7 per group.
Impaired biotransformation of GTN is recognized as a
critical factor in the development of GTN tolerance, which
is underpinned by reduced expression and activity of ALDH-
2 in both the ex vivo and in vivo setting (Sydow et al.,
2004; Hink et al., 2007). To test the hypothesis that serelaxin
increases GTN biotransformation, we used an in vivo model
of low-dose GTN tolerance. This low-dose GTN resulted in
a diminished vasodilator response to GTN, accompanied by a
reduction in ALDH-2 expression in the rat aorta, consistent
with many other studies that used relatively high doses of
GTN. More importantly, we showed that serelaxin co-infusion
increased ALDH-2 expression, decreased superoxide generation
and improved GTN-induced relaxation in the rat aorta. Due
to the limited availability of the tissue, we are unable to
measure ALDH-2 activity which is a more appropriate than
evaluation of protein/gene expression. Reduction of oxidative
stress with antioxidant treatments increases ALDH-2 activity
and restores GTN vasodilator capacity, providing further
evidence that ROS is an important contributing factor in the
development of nitrate tolerance (Sydow et al., 2004; Hink et al.,
2007).
Serelaxin attenuates several markers of oxidative stress in
a number of disease settings (Dschietzig et al., 2012; Collino
et al., 2013; Sasser et al., 2014). Specifically, ex vivo serelaxin
treatment reduces tumor necrosis factor-α stimulated superoxide
and nitrotyrosine formation in the rat aorta (Dschietzig et al.,
2012). Furthermore, serelaxin significantly decreases free radical
species associated with renal ischemia reperfusion injury, while
upregulating the endogenous antioxidant enzymes manganese
and copper zinc SODs (Collino et al., 2013). Thus, it is logical
to hypothesize that serelaxin may reduce ROS levels in the
setting of GTN tolerance. Indeed, our data demonstrated that
GTN treatment significantly increased superoxide production
in the rat aorta, and importantly, serelaxin treatment reduced
this. Taken together, we suggest that serelaxin reduces vascular
oxidative stress, resulting in enhanced ALDH-2 and GTN-
induced relaxation in the rat aorta.
An alternative potential mechanism in which ALDH-2
expression and activity may be modulated by serelaxin is through
the PI3K/Akt-dependent signaling pathway. Phosphorylation of
Akt increases the expression of ALDH-2 in the heart and human
lung epithelial cells, which can be inhibited by the PI3K inhibitor,
wortmannin (Xu et al., 2006; Yu et al., 2014). This suggests
that ALDH-2 expression is regulated by PI3K/Akt-dependent
signaling pathway. The receptors for relaxin, RXFP1 are localized
to the vascular smooth muscle cells in the rat aorta (Jelinic
et al., 2014). Activation of RXFP1 stimulates the PI3K/Akt-
dependent signaling pathway (Conrad, 2010; McGuane et al.,
2011b), leading to NO-dependent effects, including vasodilation
(Leo et al., 2014b). Thus, we propose RXFP1 activation in
the vascular smooth muscle cells by serelaxin stimulates PI3K-
dependent phosphorylation of Akt, and increase the expression
of cytosolic ALDH-2 expression (Beretta et al., 2012). As a
result, biotransformation of GTN is enhanced, preventing the
development of GTN tolerance.
A consequence of GTN tolerance is endothelial dysfunction
and cross-tolerance to other nitrovasodilators. However, there
is considerable variation between studies on the effective
duration of GTN treatment required to induce endothelial
dysfunction and cross-tolerance to other nitrovasodilators.
Endothelial dysfunction, cross-tolerance to NO donors and
impaired endothelium-derived NO were observed in rabbit aorta
after 3 days of chronic GTN treatment (Münzel et al., 1995).
Similarly, 3 days of GTN infusion caused a small but significant
reduction in ACh-mediated relaxation in the rat aorta, but there
was no cross-tolerance to DEA/NO (Irvine et al., 2011). Six days
of chronic nitrate treatment also led to decreased ACh-mediated
blood flow in the forearm of healthy human subjects (Gori et al.,
2001). In our study, despite increased vascular oxidative stress, we
were unable to achieve endothelial dysfunction in the rat aorta or
cross tolerance in response to 3 days of GTN infusion in vivo,
as determined by comparable relaxation responses to ACh and
DEA/NO. Furthermore, there were no changes to basal NOS
activity (determined pharmacologically) or enos, Gtpch1 and Dhfr
gene expression. This phenomenon has been reported in other
studies; for example endothelial function is preserved despite
increased superoxide production in diabetic carotid arteries
(Leo et al., 2010) and the aorta of relaxin-deficient mice (Ng
et al., 2015). This may be due to compensatory changes in the
mechanisms of endothelium-dependent relaxation in response to
increased oxidative stress (Leo et al., 2010; Ng et al., 2015). It
is also possible that we did not observe endothelial dysfunction
because our study used a clinically relevant, low-dose of GTN
which is at least 30-fold lower than other studies (Irvine et al.,
2011), which reported endothelial dysfunction but no cross
tolerance to DEA/NO in the rat aorta. Similar to Münzel and
colleagues (Daiber et al., 2004) who used relatively higher doses
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FIGURE 5 | Concentration-response curve to (A) DEA/NO and (B) ACh in endothelium-intact aorta from control, GTN+placebo or GTN+serelaxin rats for 3 days.
Values are expressed as mean ± SEM, n = 6–11 per group. pEC50 and maximum relaxation (Rmax) values were shown in Table 2.
FIGURE 6 | Quantitative analysis of (A) Gch1, (B) Dhfr, and (C) Nos3 mRNA expression in the aorta from control, GTN+placebo or GTN+serelaxin rats for 3 days.
(D) Basal NOS activity in endothelium-intact aorta from control, GTN+placebo or GTN+serelaxin rats for 3 days. In each group of experiments, aortae were
pre-contracted with phenylephrine (PE) to a similar level (∼20% of KPSS contraction) before the addition of L-NAME (200 µmol L–1). n = 5–8 per group. Values are
2–1Ct ± SEM. # significantly different to GTN+placebo, P < 0.05 (one-way ANOVA, Tukey’s post hoc test).
of GTN, we also successfully established an animal model with
GTN tolerance, underpinned by reduced ALDH-2 expression
and increased oxidative stress. More importantly, in this animal
model, we demonstrated that serelaxin treatment prevented the
development of GTN tolerance which was the primary objective
of the present study. We also suggest that the development
of nitrate tolerance is an early event and precedes endothelial
dysfunction and/or cross-tolerance in the rat aorta.
Serelaxin treatment in rats enhances endothelium-
dependent relaxation in vascular-region dependent
manner. This is achieved through activation of various
endothelium-derived vasodilators including NO and
PGI2 (Jelinic et al., 2014; Leo et al., 2014b, 2016c).
Specifically, in the rat aorta, the increase in NO is
achieved through increased phosphorylation of eNOS after
2 days but not 3 days of serelaxin treatment. Consistent
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with previously reported findings (Leo et al., 2016c), serelaxin
treatment for 3 days had no effect on either basal NOS activity,
or ACh-mediated relaxation in the aorta. Despite the lack
of functional changes in endothelium-derived NO-dependent
relaxation, serelaxin caused a significant increase in Dhfr
expression. Thus it appears that serelaxin may be influencing the
signaling machinery of the eNOS pathway, perhaps by regulating
DHFR.
CONCLUSION
Our study demonstrates that serelaxin attenuates the
development of GTN tolerance in the rat and mouse aorta.
More importantly, serelaxin’s ability to reverse nitrate tolerance
is achieved by decreasing superoxide production and increasing
ALDH-2 expression. We suggest that co-administration of
serelaxin has the potential to improve nitrate efficacy clinically
for AHF patients.
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